Shares of HIMS experienced a dramatic decline today following the unexpected termination of its partnership with pharmaceutical giant Novo Nordisk. Investors interpreted negatively to the news, sending its stock price plummeting by over fifteen percent. The reason for the collapse of the partnership remains unclear, but industry analysts speculate